---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-045464"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:37:10.667814+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine appoints Pamela Stephenson as CCO; grants inducement equity award

## Summary
- Pamela Stephenson, MPH, named Chief Commercial Officer effective Feb 26, 2024.
- Stephenson has 25+ years biopharma experience, most recently CCO of Albireo (acquired by Ipsen).
- Inducement award: option to purchase 55,000 shares and RSU for 36,666 shares under Nasdaq Rule 5635(c)(4).
- Option vests 25% on first anniversary, then monthly; RSU vests in four equal annual installments.
- Company is clinical-stage biopharma focused on serious hematologic diseases (NASDAQ:IRON).

## SEC filing metadata
- accession: 0001193125-24-045464
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524045464/0001193125-24-045464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524045464/d794509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-045464
- JSON: https://secwatch.observer/filing/0001193125-24-045464.json
- Plain text: https://secwatch.observer/filing/0001193125-24-045464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.